IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)

Официальное название

A Randomized, Controlled, Double-Blind, Multicenter, Phase Ⅲ Study to Evaluate the Efficacy and Safety of IMM01 (Timdarpacept) in Combination With Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)

Обзор

This study is a randomized, controlled, double-blind, multicenter, phase Ⅲ clinical study to evaluate the efficacy of IMM01(timdarpacept) in combination with azacitidine versus placebo in combination with azacitidine in patients with newly diagnosed chronic leukemia monocytic (CMML1-2).Primary endpoint are Complete remission rate and Overall survival.

Вмешательства

• Препарат IMM01
  IV infusion
• Препарат Azacitidine
  subcutaneous injection
• Препарат Placebo
  IV infusion

Первичные конечные точки

• Complete remission( CR) rate [Срок оценки: approximately 24 months]
• Overall survival (OS) [Срок оценки: approximately 24 months]

Вторичные конечные точки (8)

• Event-free survival(EFS) [Срок оценки: approximately 24 months]
• Progression-free survival(PFS) [Срок оценки: approximately 24 months]
• Time to response (TTR) [Срок оценки: approximately 24 months]
• overall response rate(ORR) [Срок оценки: approximately 24 months]
• Duration of response(DOR) [Срок оценки: approximately 24 months]
• Red blood cell transfusion independence (RTI) [Срок оценки: approximately 24 months]
• Complete remission(CR) rate [Срок оценки: approximately 24 months]
• Time to transformation to acute myeloid leukemia [Срок оценки: approximately 24 months]

Критерии участия

Критерии включения

• Age ≥ 18 years old, regardless of gender;
• Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.
• Life expectancy ≥ 12 weeks;
• Patients with CMML diagnosed according to WHO 2016 criteria, including CMML-1 and CMML-2;
• White blood cell count ≤ 13×10⁹/L before the first treatment with the study drug (hydroxyurea and leukapheresis are allowed).
• Patients must be treatment-naïve to any systemic agents for CMML (e.g., azacitidine, decitabine,chemotherapy<1 cycle, and the washout period should be more than 28 days, which is acceptable.), allogeneic stem cell transplant for CMML. Note: During screening and study participation, subjects may continue oral corticosteroids for diseases other than CMML (e.g. asthma) at a stable daily dose equivalent to ≤ 10 mg prednisone. In addition, supportive care in the form of blood transfusions or growth factors is not considered prior therapy in this case and is permitted prior to and as needed during the study.

Критерии исключения

• Previous treatment with anti-CD47 monoclonal antibody/SIRPα fusion protein;
• History of allogeneic stem cell transplant and other organ transplants; Patients who have undergone autologous haematopoietic stem cell transplant;
• Prior diagnosis of: therapy-related Myelodysplastic syndrome / Myeloproliferative neoplasm(MDS/MPN); MDS evolved from a pre-existing Myelodysplastic syndrome / Myeloproliferative neoplasm (MDS/MPN) ;other MDS/MPN including atypical chronic myeloid leukemia (aCML), juvenile myelomonocytic leukemia (JMML) and unclassifiable MDS/MPN. Patients positive for BCR-ABL fusion genes, PDGFRA, PDGFRB, and FGFR1 rearrangements need to be excluded;
• Current or history of central nervous system (CNS) leukemia, extramedullary leukemia(excluding: Enlarged spleen, enlarged liver, enlarged lymph nodes), or myeloid sarcoma;
• Diagnosis of other malignant neoplasms within 3 years prior to the first dose. Exceptions: a. Radically treated cervical carcinoma in situ or non-melanoma skin cancer,Surgery-cured prostate cancer and papillary thyroid cancer; b. a second primary cancer that has been curatively treated and has no recurrence within three years;

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Двойное слепое

Основная цель

Лечение

Центры проведения

Китай · 43 центра

• Anhui Provincial Hospital — Хэфэй
• China-Japan Friendship Hospita — Пекин
• The First Affiliated Hospital of Chongqing Medical University — Чунцин
• First Hospital of Lanzhou University — Lanzhou
• The First Affiliated Hospital of Guangxi Medical University — Nanning
• Nanfang Hospital, Southern Medical University — Гуанчжоу
• Shenzhen Second People's Hospital — Шэньчжэнь
• Zhujiang Hospital of Southern Medical University — Zhujiang
• … и ещё 35 центров

Идентификаторы

NCT: NCT06647862 · IMM01-010

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗